Volpe MA, Cabelin M, Te AE, et al. A prospective trial using saw palmetto versus finasteride in the treatment of chronic nonbacterial prostatitis (CP). Presented at: American Urological Association 2001 Annual Meeting; June 2-7, 2001; Anaheim, CA.
Emili E, Lo Cigno M, Petrone U. Clinical trial of a new drug for treating hypertrophy of the prostate (Permixon®) [in Italian].
Urologia.
1983;50:1042-1048.
Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant
Serenoa repens
in benign prostatic hyperplasia.
Br J Clin Pharmacol.
1984;18:461-462.
Tasca A, Barulli M, Cavazzana A, et al. Treatment of obstructive symptomology caused by prostatic adenoma using an extract of
Serenoa repens.
Double-blind clinical study vs. placebo [in Italian; English abstract].
Minerva Urol Nefrol.
1985;37:87-91.
Boccafoschi C, Annoscia S. Comparison of
Serenoa repens
extract with placebo by controlled clinical trial in patients with prostatic adenomatosis [in Italian].
Urologia.
1983;50:1257-1268.
Smith HR, Memon A, Smart CJ, et al. The value of Permixon® in benign prostatic hypertrophy.
Br J Urol.
1986;58:36-40.
Descotes JL, Rambeaud JJ, Deschaseaux P, et al. Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders.
Clin Drug Invest.
1995;9:291-297.
Mattei FM, Capone M, Acconcia A.
Serenoa repens
extract in the medical treatment of benign prostatic hypertrophy [in Italian].
Urologia.
1988;55:547-552.
Carraro JC, Raynaud JP, Koch G, et al. Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients.
Prostate.
1996;29:231-240.
Debruyne F, Koch G, Boyle P, et al. Comparison of a phytotherapeutic agent
(Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign
prostatic hyperplasia: a one-year randomized international study.
Eur Urol.
2002;41:497-507.
Menchini-Fabris GF, Giorgi P, Andreini F, et al. New perspectives on the use of
Pygeum Africanum
in prostato-bladder pathology [in Italian; English abstract].
Arch Ital Urol Nefrol Androl.
1988;60:313-322.
Carani C, Salvioli V, Scuteri A, et al. Urological and sexual evaluation of treatment of benign prostatic disease using at high doses [in Italian; English abstract].
Arch Ital Urol Nefrol Androl.
1991;63:341-345.
Bombardelli E, Morazzoni P.
Prunus africana
(Hook f.) kalkm.
Fitoterapia.
1997;68:205-218.
Bongi G. Tadenan in the treatment of prostatic adenoma. Anatomo-clinical study [in Italian].
Minerva Urol.
1972;24:129-139.
Rizzo M. Terapia medica dell'adenoma della prostata: Valutazione clinica comparativa tra estratto di Pygeum africanum ad alte dosi e placebo.
Farmacia Terapia.
1985;2:105-110.
Ranno S, Minaldi G, Viscusi G, et al. Efficacy and tolerability of prostate adenoma treatment with Tadenan 50 [in Italian; English abstract].
Prog Med.
1986;42:165-169.
Bassi P, Artibani W, De Luca V, et al. Standardized extract of
Pygeum africanum
in the treatment of benign prostatic hypertrophy. Controlled clinical study versus placebo [in Italian].
Minerva Urol Nefrol.
1987;39:45-50.
Barlet A, Albrecht J, Aubert A, et al. Efficacy of
Pygeum africanum
extract in the medical therapy of urination disorders due to benign prostatic hyperplasia: evaluation of objective and subjective parameters. A placebo-controlled double-blind multicenter study [translated from German].
Wien Klin Wochenschr.
1990;102:667-673.
Rhodes L, Primka RL, Berman C, et al. Comparison of finasteride (Proscar), a 5-alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5-alpha reductase inhibition.
Prostate.
1993;22:43-51.
Andro MC, Riffaud JP.
Pygeum africanum
extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience.
Curr Ther Res.
1995;56:796-817.
Kozai K, Miyake Y, Kohda H, et al. Inhibition of glucosyltransferase from
Streptococcus mutans
by oleanolic acid and ursolic acid.
Caries Res.
1987;21:104-108.
Yablonsky F, Nicolas V, Riffaud JP, et al. Antiproliferative effect of
Pygeum africanum
extract on rat prostatic fibroblasts.
J Urol.
1997;157:2381-2387.
Vontobel HP, Herzog R, Rutishauser G, et al. Results of a double-blind study on the effectiveness of ERU (extractum radicis Urticae) capsules in conservative treatment of benign prostatic hyperplasia [translated from German].
Urologe A.
1985;24:49-51.
Dathe G, Schmid H. Phytotherapy of benign prostate hyperplasia (BPH); double-blind study with stinging nettle root extract (Extractum Radicis Urticae—ERU) [translated from German].
Urologe B.
1987;27:223-226.
European Scientific Cooperative on Phytotherapy.
Urticae radix.
Exeter, UK: ESCOP; 1996-1997; Monographs on the Medicinal Uses of Plant Drugs, Fascicule 2:4.
Wilt TJ, MacDonald R, Ishani A. Beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review.
BJU Int.
1999;83:976-983.
Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
Br J Urol.
1997;80:427-432.
Kadow C, Abrams PH. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia.
Eur Urol.
1986;12:187-189.
Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
Lancet.
1995;345:1529-1532.
Berges RR, Windeler J, Trampisch HJ, et al. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.
Lancet.
1995;345:1529-1532.
Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up.
BJU Int.
2000;85:842-846.
Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group.
Br J Urol.
1997;80:427-432.
Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with Cernilton®N. Results of a placebo-controlled double-blind study [translated from German].
Urologe [B].
1988;28:301-306.
Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: a double-blind, placebo-controlled study.
Br J Urol.
1990;66:398-404.
Maekawa M, Kishimoto T, Yasumoto R, et al. Clinical evaluation of Cernilton on benign prostatic hypertrophy-a multiple center double-blind study with Paraprost [in Japanese; English abstract].
Hinyokika Kiyo.
1990;36:495-516.
Dutkiewicz S. Usefulness of Cernilton in the treatment of benign prostatic hyperplasia.
Int Urol Nephrol.
1996;28:49-53.
Becker H, Ebeling L. Conservative therapy of benign prostate hyperplasia (BPH) with Cernilton® N. Results of a placebo-controlled double-blind study [translated from German].
Urologe [B].
1988;28:301-306.
Buck AC, Cox R, Rees RWM, et al. Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton: a double-blind, placebo-controlled study.
Br J Urol.
1990;66:398-404.
Loschen G, Ebeling L. Inhibition of the arachidonate metabolism by an extract of rye pollen [in German; English abstract].
Arzneimittelforschung.
1991;41:162-167.
Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
BJU Int.
2000;86:439-442.
Marks LS, Partin AW, Epstein JI, et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia.
J Urol.
2000;163:1451-1456.
Wilt T, Ishani A, MacDonald R, et al.
Pygeum africanum
for benign prostatic hyperplasia.
Cochrane Database Syst Rev.
2002;1:CD001044.
Gerber GS, Kuznetsov D, Johnson BC, et al. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms.
Urology.
2001;58:960-964.
Preuss HG, Marcusen C, Regan J, et al. Randomized trial of a combination of natural products (cernitin, Saw Palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH).
Int Urol Nephrol.
2001;33:217-225.
McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
N Engl J Med.
2003;349:2387-2398.
Willetts KE, Clements MS, Champion S, et al.
Serenoa repens
extract for benign prostate hyperplasia: a randomized controlled trial.
BJU Int.
2003;92:267-270.
Bent S, Kane C, Shinohara K, et al. Saw Palmetto for Benign Prostatic Hyperplasia.
N Engl J Med.
2006;354:557-66.
Bent S, Kane C, Shinohara K, et al. Saw Palmetto for Benign Prostatic Hyperplasia.
N Engl J Med.
2006;354:557-66
Safarinejad MR. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study.
J Herb Pharmacother.
2006;5:1-11.
Lopatkin N, Sivkov A, Walther C, et al. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms: a placebo-controlled, double-blind, multicenter trial.
World J Urol.
2005 Jun 1. [Epub ahead of print].
Melo EA, Bertero EB, Rios LA, et al. Evaluating the efficiency of a combination of pygeum africanum and stinging nettle (urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial.
Int Braz J Urol.
2005;28:418-425.
Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of Human Prostate Cancer by Oral Administration of Green Tea Catechins in Volunteers with High-Grade Prostate Intraepithelial Neoplasia: A Preliminary Report from a One-Year Proof-of-Principle Study.
Cancer Res.
2006;66:1234-1240.
Zegarra L, Vaisberg A, Loza C, et al. Double-blind randomized placebo-controlled study of
Bixa orellana
in patients with lower urinary tract symptoms associated to benign prostatic hyperplasia.
Int Braz J Urol.
2007;33:493-501.
Supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
Am J Epidemiol.
2008 Feb 7.
Zhang W, Wang X, Liu Y, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia.
J Med Food.
2008 Mar 21.
Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia.
Cochrane Database of Systematic Reviews.
2009; CD001423.
Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.
JAMA.
2011;306(12):1344-1351.
Last reviewed July 2012 by EBSCO CAM Review Board
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.